CYTK - Cytokinetics, Incorporated
7.10 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 7.30 |
| Open | 7.30 |
| Bid | 7.00 x 100 |
| Ask | 7.30 x 100 |
| Day's Range | 7.05 - 7.50 |
| 52 Week Range | 6.75 - 17.20 |
| Volume | 225,254 |
| Avg. Volume | 388,579 |
| Market Cap | 383.458M |
| Beta | 1.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.59 |
| Earnings Date | Apr 26, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.25 |
- CNBC Videos•5 months ago
Cytokinetics CEO: Optimism still there despite ALS drug s...
Cytokinetics President and CEO Robert Blum speaks to CNBC's Meg Tirrell about the failure of the company's late-stage ALS drug trial and what he sees in future therapies for the disease.
- GlobeNewswire•7 days ago
Cytokinetics to Announce First Quarter Results on April 26, 2018
SOUTH SAN FRANCISCO, Calif., April 12, 2018-- Cytokinetics, Incorporated today announced that it is scheduled to report first quarter results on April 26, 2018 at 4:00 PM Eastern Time. Following the announcement, ...
- GlobeNewswire•last month
Cytokinetics to Present at March Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 05, 2018-- Cytokinetics, Incorporated announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following ...
- GlobeNewswire•2 months ago
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018-- Cytokinetics, Incorporated today announced that it is joining the global initiative to raise awareness of Rare Disease Day ®, an international campaign led ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CYTK earnings conference call or presentation 15-Feb-18 9:30pm GMT
Q4 2017 Cytokinetics Inc Earnings Call
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in Tile Shop Holdings, Cytokinetics, Limelight Networks, CatchMark Timber Trust, Global Payments, and Charles River Laboratories International — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tile ...
- Associated Press•2 months ago
Cytokinetics reports 4Q loss
On a per-share basis, the South San Francisco, California-based company said it had a loss of 75 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed ...
- GlobeNewswire•2 months ago
Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
Company Provides 2018 Financial Guidance and Expected Milestones; Reduced Operating Expenses vs. 2017; Over Two Years of Cash Based on Current Burn Rate. CK-2127107 Advancing in Four Clinical Trials Under ...
- ACCESSWIRE•2 months ago
Cytokinetics, Incorporated to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / Cytokinetics, Incorporated (NASDAQ: CYTK ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 15, 2018 at 4:30 PM ...
- Simply Wall St.•2 months ago
What You Must Know About Cytokinetics Incorporated’s (NASDAQ:CYTK) Major Investors
Today, I will be analyzing Cytokinetics Incorporated’s (NASDAQ:CYTK) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, the impactRead More...
- Benzinga•2 months ago
Cytokinetics Earnings Outlook
Cytokinetics (NASDAQ: CYTK ) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement. Earnings and Revenue Sell-side analysts ...
- GlobeNewswire•2 months ago
Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018-- Cytokinetics, Inc. today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the RBC Capital ...
- GlobeNewswire•2 months ago
Cytokinetics Names Robert Califf, M.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2018-- Cytokinetics, Incorporated today announced that Robert Califf, M.D., has been appointed to the company’ s Board of Directors. Califf is the Vice Chancellor ...
- GlobeNewswire•2 months ago
Cytokinetics to Announce Fourth Quarter Results on February 15, 2018
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2018-- Cytokinetics, Incorporated today announced that it is scheduled to report fourth quarter results on February 15, 2018 at 4:00 PM Eastern Time. Following the ...
- Capital Cube•5 months ago
ETFs with exposure to Cytokinetics, Inc. : November 27, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytokinetics, Inc. Here are 5 ETFs with the largest exposure to CYTK-US. Comparing the performance and risk of Cytokinetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Zacks•5 months ago
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
- 24/7 Wall St.•5 months ago
Cytokinetics Crumbles on Late-Stage Results
Cytokinetics, Inc. (NASDAQ: CYTK) saw its shares take a massive step back in Tuesday’s session after the firm reported negative results for its trial in amyotrophic lateral sclerosis (ALS). Specifically, ...
- SmarterAnalyst•5 months ago
Cytokinetics, Incorporated: Buy the Dip or Pump the Brakes?
Cytokinetics, Incorporated (NASDAQ:CYTK) shareholders were met with a rude awakening when the firm's lead ALS asset failed to meet the primary endpoint in its Phase III program, leading to the discontinued development of tirasemtiv. However, Cantor analyst Mara Goldstein has not stepped to the sidelines just yet.
- Benzinga•5 months ago
Why Is Cytokinetics Plunging Today?
Cytokinetics, Inc. (NASDAQ: CYTK ) shares are plunging in pre-market trading Tuesday on the back of negative trial results for its amyotrophic lateral sclerosis, or ALS, treatment candidate tirasemtiv ...
